Abstract
Fibromyalgia is characterized by widespread pain and tenderness, and has a significant familial component. The etiology of fibromyalgia remains unclear, but genetic factors seem to have a significant role, and are influenced by environmental factors. Research over the past two decades has demonstrated that genetic polymorphisms in the serotoninergic, dopaminergic and catecholaminergic systems of pain transmission and processing are involved in the etiology of fibromyalgia, but additional candidates continue to emerge. Fibromyalgia is thought to belong to the group of affective spectrum disorders, which include related psychiatric and medical disorders. As the concept of affective spectrum disorders continues to evolve, progress in the understanding of the genetic basis of related functional disorders, such as irritable bowel syndrome and post-traumatic-stress disorder, is aiding our understanding of the genetic basis of fibromyalgia.
Key Points
-
Familial aggregation is well established in fibromyalgia
-
In the search for a genetic basis for this aggregation, research has focused on polymorphisms in genes related to neurotransmitters involved in pain transmission and processing
-
Serotoninergic and dopaminergic markers, as well as polymorphisms in the genes encoding cathechol-O-methyl transferase and the NK1 receptor, are among the candidates studied, and a number of significant associations have been reported
-
Similar approaches have been used in studying other functional disorders, which, together with fibromyalgia, compromise the affective spectrum disorders
-
Future insight into the genetic basis of fibromyalgia might make classification and diagnosis easier, as well as improving pathophysiologic and therapeutic understanding
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gracely RH et al. (2002) Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46: 1333–1343
Staud R et al. (2001) Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91: 165–175
Hudson JI et al. (2004) Family study of fibromyalgia and affective spectrum disorder. Biol Psychiatry 56: 884–891
Hudson JI et al. (2003) Family study of affective spectrum disorder. Arch Gen Psychiatry 60: 170–177
Arnold LM et al. (2004) Family study of fibromyalgia. Arthritis Rheum 50: 944–952
Ablin NJ and Aloush V (2004) Causes of familial aggregation of fibromyalgia: comment on the article by Arnold et al. Arthritis Rheum 50: 3049–3060
Wadhwa PD et al. (2001) The neurobiology of stress in human pregnancy: implications for prematurity and development of the fetal central nervous system. Prog Brain Res 133: 131–142
Couzin J (2002) Quirks of fetal environment felt decades later. Science 296: 2167–2169
Caspi A et al. (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301: 386–389
Burda CD et al. (1986) Histocompatability antigens in the fibrositis (fibromyalgia) syndrome. Clin Exp Rheumatol 4: 355–358
Yunus MB et al. (1999) Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 26: 408–412
Wolfe F et al. (1997) Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 24: 555–559
Russell IJ et al. (1992) Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35: 550–556
Yunus MB et al. (1992) Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 19: 90–94
Offenbaecher M et al. (1999) Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 42: 2482–2488
Cohen H et al. (2002) Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 46: 845–847
Narita M et al. (2003) Association between serotonin transporter gene polymorphism and chronic fatigue syndrome. Biochem Biophys Res Commun 14: 264–266
Bondy B et al. (1999) The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 6: 433–439
Frank B et al. (2004) Mutational analysis of serotonin receptor genes: HTR3 A and HTR3B in fibromyalgia patients. Clin Rheumatol 23: 338–344
Clauw DJ and Crofford LJ (2003) Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 17: 685–701
Zubieta JK et al. (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299: 1240–1243
Gursoy S et al. (2003) Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 23: 104–107
Malt EA et al. (2003) Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 75: 77–82
Holman AJ and Myers RR (2005) A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52: 2495–2505
Buskila D et al. (2004) An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 9: 730–731
Van Tol HH et al. (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 18: 610–614
Vaeroy H et al. (1988) Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 32: 21–26
Russell IJ et al. (1994) Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37: 1593–1601
Liu Z et al. (1995) Elevated substance P level in cerebrospinal fluid from patients with fibromyalgia is contrasted by a decrease in Met-enkephalin-Arg-Phe. Analgesia 1: 4–6
Evengard B et al. (1998) Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain 78: 153–155
Terman GW (2001) Spinal mechanisms and their modulation. In Bonica's Management of Pain, B, edn 3, 73–152 (Eds Loeser JD and Chapman CR) Philadelphia: Lippincott-Williams & Wilkins
Quartara L and Maggi CA (1998) The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides 32: 1–49
McLean S (2005) Do substance P and the NK1 receptor have a role in depression and anxiety? Curr Pharm Des 11: 1529–1547
Lecci A et al. (2002) Tachykinin receptor antagonists in irritable bowel syndrome. Curr Opin Investig Drugs 3: 589–601
Duffy RA (2004) Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs 9: 9–21
Ablin JN et al. (2005) Possible association between fibromyalgia and a novel 1354G>C polymorphism in the TACR1 (substance P receptor) gene in Ashkenazi patients [abstract #656]. Arthritis Rheum 52 (Suppl): S269
Wessely S et al. (1999) Functional somatic syndromes: one or many? Lancet 354: 936–939
Hudson JI and Pope HG Jr (1990) Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology? Am J Psychiatry 147: 552–564
Hudson JI et al. (1992) Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 92: 363–367
Buchwald D and Garrity D (1994) Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 154: 2049–2053
Aaron LA et al. (2000) Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 160: 221–227
Walsh CM et al. (2001) A family history study of chronic fatigue syndrome. Psychiatr Genet 11: 123–128
Camilleri M et al. (2002) Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123: 425–432
True WR et al. (1993) A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms. Arch Gen Psychiatry 50: 257–264
Segman RH et al. (2002) Association between the dopamine transporter gene and posttraumatic stress disorder. Mol Psychiatry 7: 903–907
Lawford BR et al. (2003) D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder. Eur Neuropsychopharmacol 13: 313–320
Slotkoff AT et al. (1997) The relationship between fibromyalgia and the multiple chemical sensitivity syndrome. Scand J Rheumatol 26: 364–367
Wolfe F et al. (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33: 160–172
Gottesman II and Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636–645
Epstein SA et al. (1999) Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 40: 57–63
Krag NJ et al. (1994) A blinded, controlled evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured by standardized psychometric interview scales. Acta Psychiatr Scand 89: 370–375
Aaron LA et al. (1996) Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum 39: 436–445
Turk DC et al. (2002) Psychological evaluation of patients diagnosed with fibromyalgia syndrome: a comprehensive approach. Rheum Dis Clin North Am 28: 219–233
Ferrari R (2000) The biopsychosocial model—a tool for rheumatologists. Baillieres Best Pract Res Clin Rheumatol 14: 787–795
Williams DA (2003) Psychological and behavioural therapies in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 17: 649–665
Pellegrino MJ et al. (1989) Familial occurrence of primary fibromyalgia. Arch Phys Med Rehabil 70: 61–63
Buskila D et al. (1996) Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 26: 605–611
Buskila D and Neumann L (1997) Fibromyalgia syndrome (FM) and nonarticular tenderness in relatives of patients with FM. J Rheumatol 24: 941–944
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ablin, J., Cohen, H. & Buskila, D. Mechanisms of Disease: genetics of fibromyalgia. Nat Rev Rheumatol 2, 671–678 (2006). https://doi.org/10.1038/ncprheum0349
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0349
This article is cited by
-
Involvement of Oxidative Stress and Nerve Growth Factor in Behavioral and Biochemical Deficits of Experimentally Induced Musculoskeletal Pain in Mice: Ameliorative Effects of Heraclin
Journal of Molecular Neuroscience (2021)
-
Fibromyalgia
Nature Reviews Disease Primers (2015)
-
Synaptosomal-associated protein 25 (Snap-25) gene Polymorphism frequency in fibromyalgia syndrome and relationship with clinical symptoms
BMC Musculoskeletal Disorders (2014)
-
Chronic fatigue syndrome and fibromyalgia following immunization with the hepatitis B vaccine: another angle of the ‘autoimmune (auto-inflammatory) syndrome induced by adjuvants’ (ASIA)
Immunologic Research (2014)
-
Candidate gene studies of fibromyalgia: a systematic review and meta-analysis
Rheumatology International (2012)